Uppsala 12thDecember 2018
Nanexa receives notification of imminent US patent grant
The US patent office has now issued an “Issue Notification” in respect Nanexa´s US patent application regarding the Company’s drug delivery platform PharmaShell®. Although, technically-speaking, a patent can be withdrawn from issuance at any time up to the actual grant, should new information come to light, all being well, the Issue Notification states that a patent will issue on January 1, 2019 as US 10,166,198.
Nanexa’s CEO David Westberg comments:
The next step of the US Patent Office’s granting process has now taken place. We look forward to obtaining an issued US patent for PharmaShell® in accordance with the estimated timeline.
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: email@example.com
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.